Form D · Biotechnology

Vizgen, Inc.

Waltham, MA · CIK 0001790415

Offering snapshot reported Jan 12, 2026 · SEC filing

Reported sold
$47.8M
Offering amount: $50M
Investors reported
9
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 29, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 12, 2026Initial$47,788,714No comparison9SEC filing
Oct 7, 2025Initial$3,500,000No comparison7SEC filing
Oct 22, 2024Initial$107,575,628No comparison61SEC filing
May 5, 2022Initial$85,199,997No comparison15SEC filing
Apr 8, 2021Initial$36,999,998No comparison12SEC filing
Oct 15, 2019Initial$13,999,997No comparison3SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-569582

Source: Form D, filed Jan 12, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Seth Benson Executive
Robert Carson Director, Executive
Keith Crandell Director
Marijn E. Dekkers Director
Dr. Philip Gardella Executive
Philip Gardella Executive
Chris Guiffre Executive
Dr. Jiang He Executive
Andrea Jackson Director
Simona Levi Executive
Terry Lo Director
Matthew Posard Director
Christian Uhrich Director
Christian Urhich Director
David Walt Director
Dr. Peidong Wang Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
150 Bear Hill Road
Waltham, MA, 02451